Head and Neck Squamous Cell Carcinoma
📧 Sign up to get email alerts when something new happens for Head and Neck Squamous Cell Carcinoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2026-02-27Clinical Trial Update: Predicting Immunotherapy Efficacy in Head and Neck Squamous Cell Cancer
A clinical trial investigating biomarkers to predict immunotherapy efficacy in head and neck squamous cell carcinoma has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2025-12-19Clinical Trial Update: Time Restricted Eating (TRE) in Metastatic Head and Neck Squamous Cell Cancer (mHNSCC) or Unresectable or Metastatic Renal Cell Carcinoma (RCC) [NA]
A clinical trial investigating time-restricted eating in metastatic head and neck squamous cell carcinoma and unresectable or metastatic ren…
-
CLINICAL_TRIALS withdrawal · 2025-12-17Clinical Trial Update: Phase I/II Open Label Study Evaluating the Safety and Efficacy of Combining STAT3 Inhibition (TTI-101) With Anti-PD-1 Therapy (Pembrolizumab) in Patients With Recurrent or Metastatic (RM) Head and Neck Squamous Cell Carcinoma (HNSCC) [Phase 1, Phase 2]
A Phase I/II open-label trial of combining the STAT3 inhibitor TTI-101 with pembrolizumab for recurrent or metastatic head and neck squamous…
-
CLINICAL_TRIALS withdrawal · 2025-12-08Clinical Trial Update: Randomized Pre-surgical Window-of-Opportunity Trial of TTI-101 in Patients With Stage II-IV Resectable HPV-negative Squamous Cell Carcinoma of the Head and Neck [EARLY_Phase 1]
A randomized pre-surgical window-of-opportunity trial of TTI-101 in HPV-negative stage II-IV resectable head and neck squamous cell carcinom…
-
CLINICAL_TRIALS withdrawal · 2025-11-19Clinical Trial Update: Neoadjuvant Radiotherapy Plus Targeted Therapy and Immunotherapy vs. Targeted Therapy Plus Immunotherapy in Resectable HNSCC [Phase 2]
Phase 2 trial investigating neoadjuvant radiotherapy combined with targeted therapy and immunotherapy versus targeted therapy and immunother…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2025-07-10Clinical Trial Update: Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamous Cell Carcinoma (SCC) of the Head and Neck: The PANTHERAS [Phase 1, Phase 2]
A Phase 1/2 study of frontline pembrolizumab plus valemetostat for PD-L1 positive, HPV-negative recurrent/metastatic squamous cell carcinoma…
-
CLINICAL_TRIALS withdrawal · 2025-04-27Clinical Trial Update: Chemo-embolization for Head and Neck Cancer [Phase 2]
The Phase 2 trial of chemo-embolization for head and neck squamous cell carcinoma has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2025-04-04Clinical Trial Update: Vorinostat in Combination With Chemoradiation in Locally Advanced HPV Negative HNSCC [Phase 2]
Phase 2 trial of vorinostat with chemoradiation for locally advanced head and neck squamous cell carcinoma has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2025-03-11Clinical Trial Update: Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN [Phase 2]
A Phase 2 trial evaluating RP3 in combination with Nivolumab and other therapy for locoregionally advanced or recurrent head and neck squamo…
-
CLINICAL_TRIALS withdrawal · 2025-02-24Clinical Trial Update: QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy [Phase 1, Phase 2]
The QUILT-3.047 trial evaluating ImmunityBio's NANT vaccine for head and neck squamous cell carcinoma has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2025-02-14Clinical Trial Update: NT-I7 for the Treatment of Recurrent Squamous Cell Carcinoma of Head and Neck Undergoing Surgery [Phase 1]
A Phase 1 trial of NT-I7 for recurrent squamous cell carcinoma of the head and neck undergoing surgery was terminated.
-
CLINICAL_TRIALS withdrawal · 2024-07-25Clinical Trial Update: Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck Cancer [Phase 2]
Phase 2 trial evaluating Xevinapant added to standard radiation therapy plus cisplatin/carboplatin for head and neck cancers has been withdr…
-
CLINICAL_TRIALS withdrawal · 2021-05-10Clinical Trial Update: Maintenance Immune Check-point Inhibitor Following Post-operative Chemo-radiation in Subjects With HPV-negative HNSCC [Phase 3]
A Phase 3 trial evaluating maintenance immune checkpoint inhibitor after post-operative chemoradiation in HPV-negative head and neck squamou…
-
CLINICAL_TRIALS withdrawal · 2019-02-12Clinical Trial Update: Image Guided Intensity Modulated Reirradiation (IG-IMRT) With Cetuximab for Locoregionally Confined Recurrent Head and Neck Squamous Cell Carcinoma [Phase 2]
A Phase 2 trial evaluating image-guided IMRT with cetuximab for locoregionally confined recurrent head and neck squamous cell carcinoma has …
-
CLINICAL_TRIALS withdrawal · 2017-06-08Clinical Trial Update: Pharmacodynamic Effects and Predictive Biomarkers With Ruxolitinib in Operable Head and Neck Cancer [EARLY_Phase 1]
The document reports the withdrawal of a Phase 1 trial evaluating pharmacodynamic effects and predictive biomarkers of ruxolitinib in operab…
-
CLINICAL_TRIALS withdrawal · 2017-04-24Clinical Trial Update: Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction [Phase 1]
A Phase 1 clinical trial of talazoparib in patients with advanced or metastatic solid tumors unsuitable for surgery and with liver or kidney…
-
CLINICAL_TRIALS withdrawal · 2017-02-08Clinical Trial Update: Postoperative Concurrent Chemoradiation for Head and Neck Cancer With Multiple Minor Risk [NA]
A clinical trial evaluating postoperative concurrent chemoradiation for head and neck squamous cell carcinoma has been terminated.
-
CLINICAL_TRIALS withdrawal · 2016-09-30Clinical Trial Update: A Phase II Trial Evaluating WNT974 in Patients With Metastatic Head and Neck Squamous Cell Carcinoma [Phase 2]
A Phase II trial evaluating WNT974 for metastatic head and neck squamous cell carcinoma has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2016-07-20Clinical Trial Update: Dose Escalation Trial of Neoadjuvant Sorafenib and Concurrent Sorafenib, Cisplatin and Radiation in Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN) [Phase 1]
A Phase 1 dose-escalation trial of neoadjuvant sorafenib with cisplatin and radiation for locally advanced head and neck squamous cell carci…
-
CLINICAL_TRIALS withdrawal · 2016-04-21Clinical Trial Update: Study of Efficacy and Safety of LJM716 and Cetuximab in Head and Neck Squamous Cell Carcinoma Patients [Phase 1, Phase 2]
A clinical trial assessing the combination of LJM716 and cetuximab for head and neck squamous cell carcinoma has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2014-07-02Clinical Trial Update: A Post-marketing Surveillance Study on Erbitux in Combination With Platinum-based Chemotherapy in Metastatic/Recurrent Squamous Cell Cancer of the Head and Neck
A post-marketing surveillance trial of cetuximab (Erbitux) plus platinum-based chemotherapy for metastatic or recurrent head and neck squamo…
-
CLINICAL_TRIALS withdrawal · 2013-12-11Clinical Trial Update: Entolimod in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Receiving Cisplatin and Radiation Therapy [Phase 1]
The Phase 1 trial evaluating entolimod in combination with cisplatin and radiation for stage III-IV head and neck squamous cell carcinoma wa…
-
CLINICAL_TRIALS withdrawal · 2013-05-15Clinical Trial Update: Botanical Therapy in Treating Mucositis in Patients With Head and Neck Cancer Who Have Undergone Chemoradiation Therapy [Phase 2]
Phase 2 trial evaluating a botanical therapy to treat mucositis in patients with head and neck cancer after chemoradiation has been withdraw…
-
CLINICAL_TRIALS withdrawal · 2013-04-05Clinical Trial Update: Phase II Study of Cetuximab With or Without OSI-906 in Head and Neck Squamous Cell Carcinoma (HNSCC) [Phase 2]
A Phase II trial evaluating cetuximab with or without OSI-906 in head and neck squamous cell carcinoma has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2012-08-01Clinical Trial Update: Assessment of Head and Neck Tumor Hypoxia Using 18F-Fluoromisonidazole [NA]
A clinical trial evaluating head and neck tumor hypoxia with the PET tracer 18F-Fluoromisonidazole has been withdrawn.